Health ❯Healthcare ❯Drug Development

Regulatory Affairs

Animal Testing Alternatives FDA Approval FDA Submissions Drug Discontinuation Clinical Trials

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

The Q3 closing will add Blueprint’s FDA-approved systemic mastocytosis therapy Ayvakit alongside late-stage candidates to Sanofi’s portfolio.

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab

FDA Launches Immediate Plan to Replace Animal Testing with Human-Relevant Methods

FDA Launches Roadmap to Phase Out Animal Testing in Drug Development

GSK Agrees to $2.2 Billion Settlement Over Zantac Cancer Claims

Alnylam's Vutrisiran Shows Mixed Results in Cardiomyopathy Study